Analyzing Nuvectis Pharma (NASDAQ:NVCT) & Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Nuvectis Pharma (NASDAQ:NVCT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility & Risk

Rhythm Pharmaceuticals has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500.

Insider and Institutional Ownership

96.8% of Nuvectis Pharma shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Rhythm Pharmaceuticals and Nuvectis Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76 million	41.34	-$196.54 million	($3.13)	-36.57
Nuvectis Pharma	N/A	N/A	-$26.44 million	($1.31)	-14.66

Nuvectis Pharma has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rhythm Pharmaceuticals and Nuvectis Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Rhythm Pharmaceuticals and Nuvectis Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1	2	14	0	2.76
Nuvectis Pharma	1	0	2	0	2.33

Rhythm Pharmaceuticals currently has a consensus price target of $136.40, indicating a potential upside of 19.17%. Nuvectis Pharma has a consensus price target of $35.00, indicating a potential upside of 82.29%. Given Nuvectis Pharma’s higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Rhythm Pharmaceuticals.

Summary

Nuvectis Pharma beats Rhythm Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About Nuvectis Pharma

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.